home / stock / crbu / crbu news

CRBU News and Press, Caribou Biosciences Inc.

Stock Information
Company Name: Caribou Biosciences Inc.
Stock Symbol: CRBU
Market: NASDAQ
Menu
CRBU CRBU Quote CRBU Short CRBU News CRBU Articles CRBU Message Board
Get CRBU Alerts

News, Short Squeeze, Breakout and More Instantly...
CRBU - Buy Recommendation Issued On CRBU By H.C. Wainwright

2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
CRBU - Caribou stock plunges 30% amid study update, Evercore downgrade

2024-06-03 10:02:56 ET More on Caribou Bioscience Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value Caribou Biosciences GAAP EPS of -$0.46 misses by $0.05, revenue of $2.43M beats by $0.01M Caribou Biosciences received IND clearance from FDA for ...

CRBU - US Companies Moving the Markets, Morning edition
Mon, Jun 03, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...

CRBU - Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to...
CRBU - Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following event and investor conferences: • Caribou...

CRBU - PLAB, ARRY and SYM are among after hour movers

2024-05-24 16:58:54 ET Gainers: Photronics ( PLAB ) +6% . Replimune Group  ( REPL ) +4% . Caribou Biosciences ( CRBU ) +3% . Symbotic  ( SYM ) +3% . Arhaus ( ARHS ) +3% . Losers: OneMedNet  ( ONMD ) -...

CRBU - ASTS, CRBU and DOMO are among after hour movers

2024-05-23 16:47:49 ET Gainers: Ross Stores ( ROST ) +6% . Frontier Group Holdings ( ULCC ) +4% . Caribou Biosciences ( CRBU ) +4% . Absci Corporation ( ABSI ) +3% . Protara Therapeutics ( TARA ) +3% . Losers: Domo ( DO...
CRBU - SBRA, GH and CRBU are among after hour movers

2024-05-20 16:47:47 ET Gainers: Maravai LifeSciences  ( MRVI ) +5% . Caribou Biosciences ( CRBU ) +4% . Greenidge Generation Holdings  ( GREE ) +4% . Cipher Mining  ( CIFR ) +4% . SIGA Technologies  ( SIGA ) +4%...

CRBU - Underperform Recommendation Issued On CRBU By H.C. Wainwright

2024-05-16 16:30:03 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CRBU on May 16, 2024 02:01PM ET. The previous analyst recommendation was Underperform. CRBU was trading at $3.585 at issue of the analyst recommendation. The overall analyst consensus :...

CRBU - Caribou Bioscience GAAP EPS of -$0.46 misses by $0.05, revenue of $2.43M beats by $0.01M

2024-05-07 17:46:38 ET More on Caribou Bioscience Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value Caribou Biosciences received IND clearance from FDA for its lupus treatment Caribou Bioscience GAAP EPS of -$0.39 in-line, revenue of $3.56M misse...
Next 10